ABT Stock Slides Near 52-Week Low as Selling Pressure Mounts

By TrendSpider Editor

Abbott Laboratories shares dropped 2.39% to $100.27 on Monday, April 13, 2026, putting the stock within striking distance of its 52-week low of $99.34. That low was actually tested intraday, with yesterday's session touching $99.34 before bouncing to a high of $102.77. With the stock now sitting jus

ABT Stock Slides Near 52-Week Low as Selling Pressure Mounts

Abbott Laboratories shares dropped 2.39% to $100.27 on Monday, April 13, 2026, putting the stock within striking distance of its 52-week low of $99.34. That low was actually tested intraday, with yesterday's session touching $99.34 before bouncing to a high of $102.77. With the stock now sitting just $0.93 above its yearly floor and far below the 52-week high of $139.05, ABT is trading at one of its most compressed levels in the past year.

Key Drivers of the ABT Stock Move

• Main Catalyst: ABT fell 2.39% to close at $100.27, breaching the psychologically important $100 level intraday as price touched the 52-week low of $99.34. The proximity to this floor makes the current price level a critical technical inflection point for investors and traders watching the name.
• Bull Case: The $99.34 level has now acted as a tested intraday support point, and the stock managed to recover off that low to close above it. A hold at this level could attract value-oriented buyers given that ABT is trading roughly 27.9% below its 52-week high of $139.05, a significant discount to its recent range.
• Bear Case: A daily close below the $99.34 52-week low would mark a technical breakdown with no established support underneath it. The 2.39% single-session loss reflects meaningful conviction from sellers, and continued pressure could accelerate if that floor gives way.

The forward setup for ABT is fragile from a technical standpoint. The stock is pinned near its yearly low with a wide gap between current levels and the $139.05 high set over the past 52 weeks, suggesting the trend has been decisively lower. For the bulls to regain control, ABT would need to establish a credible base around the $99 to $100 zone and see a meaningful shift in buying interest. Any failure to hold the $99.34 level on a closing basis would likely draw additional technical selling and could shift sentiment further to the downside. Investors will be watching closely to see whether this area serves as a durable floor or merely a pause in the broader decline.

ABT Seasonality

April has historically been an active month for Abbott Laboratories, as the company typically reports first-quarter earnings during this period, which can create elevated volatility around the mid-month timeframe. Traders should remain alert to any scheduled announcements in the coming weeks that could serve as a catalyst for a directional move off the current support level.

ABT Relative Performance

ABT's 2.39% single-session decline on April 13, 2026, is a notable underperformance, particularly given that a move of this magnitude pushes the stock to a 52-week low. Without comparative peer or index data available, the magnitude of the loss relative to ABT's own historical range tells the story clearly: at $100.27, the stock is sitting just 0.94% above its 52-week floor of $99.34 and roughly 27.9% below its 52-week ceiling of $139.05, reflecting a sustained period of underperformance within its own trading history over the past year.